Very poor form. I'm gutted. Back to the drawing board. Looking very much like the deal might now fall over. Asset sale or alternative offer now likely.Greedy buggers.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%